|
Stomach Carcinoma
|
0.600 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Stomach Carcinoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Introduction</b>: CT-P6 (trastuzumab-pkrb, Herzuma) is a trastuzumab biosimilar approved for use in HER2 positive breast cancer and HER2 positive gastric cancer.
|
31507219 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
48 patients with HER2 positive advanced GCs accepting trastuzumab treatment were retrospectively analyzed.
|
28388541 |
2017 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Gastric cancer (GC) has also been slow to benefit from biomarker discovery and development and the successful utilisation of targeted therapies, with the exception of trastuzumab in HER2 positive cancers.
|
30597479 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER-2/neu-overexpressing tumors detected by immunohistochemistry amounted to 19% of primary gastric cancers and HLA-A2-positive patients with gastric cancer were 31% of primary gastric-cancer cases.
|
11857411 |
2002 |
|
Stomach Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ERBB2 kinase domain mutation in a gastric cancer metastasis.
|
16309427 |
2005 |
|
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
HER2 is highly expressed in a significant proportion of breast cancer, ovarian cancer, and gastric cancer.
|
20385184 |
2010 |
|
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
HER2 overexpression is associated with metastasis-the main cause of death in individuals with gastric cancer.
|
20460098 |
2010 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Her-2-targeted therapy has recently been shown to be beneficial for patients with advanced gastric cancer.
|
21107094 |
2010 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 testing in gastric carcinoma is a new field, opening several opportunities: for patients with gastric cancer, this is a new promising therapeutic option; for pathologists, strengthening our role in therapy selection and emphasizing our duty of providing accurate and reproducible HER2 testing results; for all interested in understanding the biology of gastric and GEJ cancer and in discovering new possible molecular therapy targets.
|
21169738 |
2011 |
|
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
HER-2/neu (c-erbB-2, HER2) gene amplification and protein overexpression have been associated with poor prognosis in several solid tumors, including breast and gastric cancer.
|
21267790 |
2011 |
|
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
HER2 overexpression was significantly associated with high grade, advanced stage, high Ki-67 labelling index value and death from gastric cancer.
|
22067088 |
2012 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Human epidermal growth factor receptor 2 status in gastric carcinoma is comparable to previous studies with good concordance between IHC and SISH; all IHC 2+ and unusual patterns should be assessed with ISH studies; heterogeneity of tumour HER2 overexpression/amplification is common with possible implications for HER2 testing; and HER2 overexpression appears sufficiently specific to be considered a potential diagnostic biomarker of dysplasia.
|
22092394 |
2011 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology.
|
22253521 |
2012 |
|
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
HER2 over-expression was detected in 23 out of 49 (46.9%) patients with intestinal GC, and 9 out of 35 (25.7%) patients with diffuse GC.
|
22654433 |
2012 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 positivity found in 7.3 % of GCs was significantly associated with older age, male gender, intestinal histology, upper third in location, higher lymph node stage (p < .002), and advanced AJCC stage (p = .033).
|
23274580 |
2013 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.
|
23348899 |
2013 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 was not a prognostic factor for gastric cancer in our study.
|
23788757 |
2013 |
|
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
HER2 mRNA expression in GC cell lines was increased by coculture with PBMCs.
|
24185685 |
2014 |
|
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
HER2 overexpression is seen in 7-34% of GC cases.
|
24458107 |
2014 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.
|
25357111 |
2014 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.
|
25512144 |
2016 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 testing in breast and gastric cancer is critical not only as a prognostic tool but also as a predictive marker for response to the humanized monoclonal antibody trastuzumab.
|
25578771 |
2015 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
|
25611242 |
2015 |